Undisclosed OUD Program
Opioid Use Disorder
Pre-clinicalActive
Key Facts
About Epiodyne
Epiodyne is an early-stage biotech tackling the opioid crisis through a novel approach to opioid pharmacology. The company aims to engineer small-molecule opioids that retain potent analgesic properties while minimizing the risks of addiction, misuse, and respiratory depression that characterize current opioids. Operating in a high-need but challenging regulatory and scientific environment, Epiodyne represents a new wave of companies seeking to rehabilitate the opioid class for therapeutic use. As a private, pre-clinical company, its success hinges on validating its platform and advancing candidates into clinical development.
View full company profileTherapeutic Areas
Other Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| FP-004 (SIF Formulation) | Foresee Pharmaceuticals | Preclinical |
| Vaxine Opioid Addiction Vaccine | Vaxine | Preclinical |
| Safer Ibogaine Analogs | Gilgamesh Pharmaceuticals | Pre-clinical/Research |
| AM-510 | Aion Medicines | Discovery |
| Naltrexone Implant | Delpor | Phase 1 |
| Platform Expansion | Amygdala Neurosciences | Research |
| AQL™-Naltrexone | Plumb Pharmaceuticals | Pre-clinical |
| MEB-1170 | Mebias Discovery | Phase 1 |
| SUBLOCADE® | Indivior PLC | Marketed |